Bailly Alyssa R, Hester Garrett M, Alesi Michaela G, Buresh Robert J, Feito Yuri, Mermier Christine M, Ducharme Jeremy B, VanDusseldorp Trisha A
Department of Exercise Science and Sport Management, Kennesaw State University, 520 Parliament Garden Way NW, Kennesaw, Georgia, 30144, United States of America.
Department of Health, Exercise, and Sports Sciences, University of New Mexico, 200 Cornell Dr, Albuquerque, NM, 87131, United States of America.
J Bone Miner Metab. 2025 May;43(3):304-314. doi: 10.1007/s00774-025-01592-0. Epub 2025 Mar 7.
This study aimed to investigate the effects of quercetin (a plant-based flavonoid) supplementation over 90 days on prominent bone turnover markers (BTMs), inflammatory markers, bone mineral density (BMD), body composition, and physical function in postmenopausal women.
Thirty-three healthy postmenopausal women were recruited to participate in a double-blind, placebo-controlled investigation. Participants were randomized into one of two supplement groups: (1) 500 mg of quercetin (QUE) once daily or (2) 500 mg of methylcellulose (placebo; PLB) once daily. Pre- and post-testing visits included assessments of BTMs (i.e., osteocalcin [OC], procollagen type I N-terminal propeptide [PINP], and type I collagen cross-linked C-terminal telopeptide [CTX]), inflammatory markers (i.e., interleukin [IL]-6, tumor necrosis factor-alpha [TNF-α], and C-reactive protein [CRP]), BMD measurements, body composition measurements, and physical function including timed up and go and handgrip strength.
The QUE group increased OC (p = 0.016; d = 0.89), PINP (p = 0.030; d = 0.64), and CTX (p = 0.023; d = 0.91) levels and decreased IL-6 (p = 0.045; d = 0.73) and TNF-α (p = 0.021; d = 0.90) levels compared to PLB. CRP (p = 0.448; d = 0.34), body composition (p > 0.05), and physical function (p > 0.05) remained unchanged.
The results suggest that QUE may better assist in controlling a normal bone turnover cycle by mediating bone formation and decreasing pro-inflammatory cytokines. However, although within the accepted range, there was an increase in the bone resorption marker and therefore, it is unclear if QUE will protect against future bone loss. Nonetheless, additional research is necessary to evaluate the bone-conserving properties of QUE among postmenopausal women.
The ClinicalTrials.gov ID number: NCT05371340.
本研究旨在调查补充槲皮素（一种植物类黄酮）90天对绝经后女性显著的骨转换标志物（BTMs）、炎症标志物、骨密度（BMD）、身体成分和身体功能的影响。
招募33名健康的绝经后女性参与一项双盲、安慰剂对照研究。参与者被随机分为两个补充剂组之一：（1）每日一次服用500毫克槲皮素（QUE）或（2）每日一次服用500毫克甲基纤维素（安慰剂；PLB）。测试前和测试后的访视包括评估BTMs（即骨钙素[OC]、I型前胶原N端前肽[PINP]和I型胶原交联C端肽[CTX]）、炎症标志物（即白细胞介素[IL]-6、肿瘤坏死因子-α[TNF-α]和C反应蛋白[CRP]）、BMD测量、身体成分测量以及身体功能，包括计时起立行走测试和握力测试。
与PLB组相比，QUE组的OC（p = 0.016；d = 0.89）、PINP（p = 0.030；d = 0.64）和CTX（p = 0.023；d = 0.91）水平升高，IL-6（p = 0.045；d = 0.73）和TNF-α（p = 0.021；d = 0.90）水平降低。CRP（p = 0.448；d = 0.34）、身体成分（p > 0.05）和身体功能（p > 0.05）保持不变。
结果表明，QUE可能通过介导骨形成和减少促炎细胞因子，更好地协助控制正常的骨转换周期。然而，尽管在可接受范围内，骨吸收标志物有所增加，因此，尚不清楚QUE是否能预防未来的骨质流失。尽管如此，仍需要进一步的研究来评估QUE在绝经后女性中的保骨特性。
ClinicalTrials.gov标识符：NCT05371340。
